.st0{fill:#FFFFFF;}

Pembrolizumab use supported in advanced melanoma 

 July 22, 2020

By  Review

(HealthDay)—Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of a BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy, according to a study published online July 20 in JAMA Oncology.

Review Renew ACLS


Review Renew ACLS is a local American Heart Association Certification Course Provider. In addition to this, we serve the Central Florida Health Care Community with Industry Related Topics. Our role in the community is growing and not limited to BLS, ACLS, and PALS Certification Courses. Resources for Jobs, Community Involvement and Respiratory Continuing Education Credits are also offered.

Cher Hamilton, founder

Health Topics:

Message Us

>
error: Content is protected !!